Reviewing the WHO guidelines for antibiotic use for sepsis in neonates and children. (21st December 2018)

• Record Type: Journal Article
• Authors: Fuchs, Aline; Bielicki, Julia; Mathur, Shrey; Sharland, Mike; Van Den Anker, Johannes N.
• Is Part Of: Paediatrics and international child health. Volume 38(2018)Supplement 1
• Page Start: S3
• Page End: S15
• Publication Date: 2018-12-21
• Subjects: Sepsis -- antibiotics -- antimicrobial resistance -- treatment guidelines; Pediatrics -- Developing countries -- Periodicals; Children -- Health and hygiene -- Developing countries -- Periodicals; Children -- Diseases -- Developing countries -- Periodicals; 618.920009172405
• DOI: 10.1080/20469047.2017.1408738
• Languages: English
• ISSNs: 2046-9047

Abstract

Abstract: Background: Guidelines from 2005 for treating suspected sepsis in low- and middle-income countries (LMIC) recommended hospitalisation and prophylactic intramuscular (IM) or intravenous (IV) ampicillin and gentamicin. In 2015, recommendations when referral to hospital is not possible suggest the administration of IM gentamicin and oral amoxicillin. In an era of increasing antimicrobial resistance, an updated review of the appropriate empirical therapy for treating sepsis (taking into account susceptibility patterns, cost and risk of adverse events) in neonates and children is necessary. Methods: Systematic literature review and international guidelines were used to identify published evidence regarding the treatment of (suspected) sepsis. Results: Five adequately designed and powered studies comparing antibiotic treatments in a low-risk community in neonates and young infants in LMIC were identified. These addressed potential simplifications of the current WHO treatment of reference, for infants for whom admission to inpatient care was not possible. Research is lacking regarding the treatment of suspected sepsis in neonates and children with hospital-acquired sepsis, despite rising antimicrobial resistance rates worldwide. Conclusions: Current WHO guidelines supporting the use of gentamicin and penicillin for hospital-based patients or gentamicin (IM) and amoxicillin (oral) when referral to a hospital is not possible are in accordance with currently available evidence and other international guidelines, and there is no strong evidence to change this. The benefit of a cephalosporin alone or in combination as a second-line therapy in regions with known high rates of non-susceptibility is not well established. Further research into hospital-acquired sepsis in neonates and children is required.